Ignyta

Ignyta

Ignyta

Kindling the revolution in personalized medicine. Helping to extinguish cancer
Type
B2b
Founded
2011
Raised
$290.5M
Follow us
Alexa global traffic share
Twitter followers
Latest funding Show all
$160,000,000
Post-IPO equity - 2017
$42,000,000
Post-IPO debt - 2016
Silicon Valley Bank Oxford Finance
Team Size
10+
Employees
Xconomy

Another Precision Step for Roche as Ignyta Drug Heads to Regulators

MedCity News

Roche's $1.7B precision medicine acquisition of Ignyta targets cancers with rare mutations

Health Strategy
Bloomberg

Roche to Buy U.S. Cancer-Drug Maker Ignyta for $1.7 Billion

Health Strategy
Xconomy

In Turnaround Saga, Ignyta Nears Crucial Phase in Cancer Drug Trial

Health Science
$42,000,000 Post-IPO debt
businesswire

Ignyta Secures $42 Million Term Loan Facility | Business Wire